Totally Implanted Vascular Access Devices-Related Infections in Oncology and Hematology: A Retrospective Single-Center Study
Blood-cancer patients on IV ports face higher infection rates than solid-tumor patients, revealing the need for tailored prevention strategies in hematology care.
A retrospective single-center study found significantly higher TIVAD infection rates in hematology (3.40/1000 person-days) vs oncology patients (1.24/1000), with Gram-negative bacteria predominating. This underscores the need for hematology-specific infection control protocols distinct from oncology standard care.
What the study was
- Study design
- Retrospective single-center study
- Population
- Oncology and hematology inpatients with TIVAD in Warsaw, 2022-2023
- Category
- Public Health
- Maturity
- Exploratory
- Journal
- J Vasc Access
Why it surfaced
Single-center retrospective, limited generalizability; incremental finding on TIVAD infection rates.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.